减持套现53亿后股价应声上涨,实控人看似错失9亿收益,实则是精准的长期资本布局。 药明康德 2025年业绩预告交出净利润翻倍答卷,核心业务高增、王牌赛道爆发,叠加专业化资本运作与战略聚焦,展现出CXO龙头的强劲韧性,而单一市场依赖的隐忧仍需警惕。此次实控人李革、张朝晖等关联方的减持,绝非临时决策,而是严格按照2025年10月底披露的计划执行,全程合规透明。彼时公司股价年内涨幅已超110%,触及...
Source Link减持套现53亿后股价应声上涨,实控人看似错失9亿收益,实则是精准的长期资本布局。 药明康德 2025年业绩预告交出净利润翻倍答卷,核心业务高增、王牌赛道爆发,叠加专业化资本运作与战略聚焦,展现出CXO龙头的强劲韧性,而单一市场依赖的隐忧仍需警惕。此次实控人李革、张朝晖等关联方的减持,绝非临时决策,而是严格按照2025年10月底披露的计划执行,全程合规透明。彼时公司股价年内涨幅已超110%,触及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.